In a Phase I trial, patients with metastatic kidney cancer who took a live biotherapeutic product alongside immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes. City of Hope, US, researchers are now in discussions with the global SWOG Cancer Research Network to design a… Read More
Researchers have developed a new antibiotic that reduced or eliminated drug-resistant bacterial infections in mouse models of acute pneumonia and sepsis while sparing healthy microbes in the gut. The drug, called lolamicin, also warded off secondary infections with Clostridioides difficile, and was effective against more than… Read More
Biomica has revealed encouraging initial findings from an ongoing Phase I clinical trial of its microbiome-based immuno-oncology candidate, BMC128, in combination with an anti-PD1 immune checkpoint inhibitor. The trial is assessing the drug in patients with non-small cell lung cancer (NSCLC), melanoma, or renal cell… Read More
EnteroBiotix, a Glasgow, UK based biotechnology company, has dosed the first patient in a clinical trial designed to evaluate EBX-102-02 for the treatment of irritable bowel syndrome (IBS). The Phase II study, named ‘TrIuMPH’ (treating IBS with an intestinal microbiota product for health) will initially enrol… Read More
By Katie Gillette, Senior Project Leader, Eliza French, Analyst, Graham Friedman, Analyst, and Olivia Qiu, Associate, DeciBio. Earlier this year, we explored the microbiome and its role in drug development across various therapeutic areas. This article will focus on one such area of great unmet need and promise: women's health. Read More
Over the past decade, the gut microbiome has gained significant interest by scientists and non-scientists alike. Recent research has shown that the bacteria and other microbes in our gut play a supporting role in immunity, metabolism, digestion, and the fight against “bad bacteria” that try to invade our bodies. Read More
Listen to this article on the DDW Podcast: An industry overview of the role of the microbiome in precision medicine, and its interplay with research tools, diagnostics, and therapeutic development. By Katie Gillette, Senior Project Leader, Eliza French, Analyst, and Graham Friedman, Analyst, DeciBio. The human microbiome refers to the vast… Read More
Paul Denslow, CEO, Intus Bio, discusses how a new approach to tracking gut bacteria can revolutionse our understanding of the microbiome and bring about new discoveries for therapeutics. It’s a long-held doctrine that there's no effective method to track the microbiome during drug research and development. This doctrine no longer… Read More
Frequent and diverse use of antibiotics may be associated with developing more severe outcomes after a Covid-19 infection, including death, UK scientists have shown. The findings, funded by Health Data Research UK and the National Institute for Health and Care Research (NIHR), act as a warning… Read More
A new study has revealed consistent biological signals in the human microbiome and other physiological signals associated with autism. The research highlights the need for long-term studies to determine autism’s underlying causes. Taking a new computational approach to the problem, a study published in… Read More
New research in mice has identified how gut bacteria alter the body’s response to PD-1 checkpoint blockade immunotherapy, currently used for the treatment of 25 forms of cancer. The findings could inform the design of treatments that boost the efficacy of cancer immunotherapy among patients with… Read More
Data generated from a C. difficile infection (CDI) model study on the ability of M3 (NTCD-M3), a non-toxigenic C. difficile strain, shows successful gut colonisation following administration of fidaxomicin and has been peer-reviewed and published in Microbiology Spectrum. The paper by Destiny Pharma, a UK-based clinical stage biotechnology company focused… Read More
Gut bacteria can influence brain health, according to a study of mice genetically predisposed to develop Alzheimer’s-like brain damage. The findings suggest a new approach to treating Alzheimer’s and other neurodegenerative diseases. Context Researchers at Washington University School of Medicine in St Louis showed that… Read More
This is the latest DDW Sitting Down With sponsored podcast, which features Dr John Couse, Vice President of Scientific Services at Taconic Biosciences, who discusses how the microbiome is transforming drug discovery and what this means for pharmaceutical and biotech companies. Couse offers detailed insight into the microbiome and outlines its role… Read More
The latest DDW Sitting Down With sponsored podcast is now available. It features Dr John Couse, Vice President of Scientific Services at Taconic Biosciences, who discusses how the microbiome is transforming drug discovery and what this means for pharmaceutical and biotech companies. Couse offers detailed insight into the microbiome and… Read More
An Oxford University study has provided the first evidence that antibiotic resistant bacteria can travel from the gut to the lung, increasing the risk of deadly infections. The findings coincide with World Antimicrobial Awareness Week and shed light on how antimicrobial resistance (AMR) arises and persists. … Read More
